ANAB
- AnaptysBio, Inc.
()
Overview
Company Summary
AnaptysBio, Inc. (ANAB) is a biotechnology company focused on the development of antibody-based therapeutics. The company specializes in developing novel antibodies that can address unmet medical needs in various disease areas.
AnaptysBio utilizes its proprietary antibody discovery technology platform, called somatic hypermutation (SHM), to identify and generate therapeutic antibodies. This platform allows the company to rapidly explore and engineer antibody candidates with improved efficacy and reduced side effects.
The company's primary focus is on developing antibodies to target inflammatory diseases, autoimmune disorders, and oncology indications. AnaptysBio's pipeline consists of multiple drug candidates at various stages of development.
The company's lead product candidate, etokimab, is being evaluated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), a chronic inflammatory disease of the sinuses. Etokimab has also shown potential in other inflammatory disorders like atopic dermatitis and asthma.
In addition to etokimab, AnaptysBio has several other antibody programs in preclinical and clinical stages of development. These programs target various disease areas, including severe asthma, inflammatory bowel disease, and metastatic cancers.
Overall, AnaptysBio is dedicated to leveraging its innovative antibody discovery platform to develop and commercialize next-generation therapeutics that can make a meaningful impact on the lives of patients suffering from a range of diseases.